Journal article

Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-kappa B Pathway Activity: A Novel Approach to a Long-Standing Enigma

Laura van Lieshout, Anja van de Stolpe, Phyllis van der Ploeg, David Bowtell, Joanne de Hullu, Jurgen Piek

CANCERS | MDPI | Published : 2020


We investigated signal transduction pathway (STP) activity in high-grade serous ovarian carcinoma (HGSC) in relation to progression-free survival (PFS) and overall survival (OS). We made use of signal transduction pathway activity analysis (STA analysis), a novel method to quantify functional STP activity. Activity of the following pathways was measured: androgen receptor (AR), estrogen receptor (ER), phosphoinositide 3-kinase (PI3K), Hedgehog (Hh), Notch, nuclear factor-kappa B (NF-κB), transforming growth factor beta (TGF-β), and Wnt. We selected HGSC samples from publicly available datasets of ovarian cancer tissue, and used repeated k-means clustering to identify pathway activity cluster..

View full abstract


Awarded by Ruby and Rose foundation

Awarded by U.S. Army Medical Research and Materiel Command

Awarded by National Health and Medical Research Council of Australia

Awarded by NHMRC Enabling Grants

Awarded by Cancer Institute NSW

Funding Acknowledgements

This study was supported by the Ruby and Rose foundation (project number R0004286). The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, the Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, the Cancer Council Tasmania, and the National Health and Medical Research Council of Australia (NHMRC; ID199600; ID400413 and ID400281). The Gynaecological Oncology Biobank atWestmead, a member of the Australasian Biospecimen Network-Oncology group, was funded by NHMRC Enabling Grants, ID 310670 and ID 628903, as well as the Cancer Institute NSW, grant IDs 12/RIG/1-17 and 15/RIG/1-16.